Nicholas Robert, MD, medical director of Data, Evidence & Insights, McKesson Life Sciences, discusses the lag time between a drug's approval and its availability in the electronic medical record (EMR) for the physician to order.
Nicholas Robert, MD, medical director of Data, Evidence & Insights, McKesson Life Sciences, discusses the lag time between a drug's approval and its availability in the electronic medical record (EMR) for the physician to order.
Transcript
What is the typical lag time between a drugs approval and its availability in the electronic health records with the physicians being able to order it?
One of the challenges is when there is a new regimen that’s been approved, how long is it going to take to get into the EMR, remembering that the electronic medical records is the platform for choosing your regimens. We recently looked at this and presented as a poster at ISPOR this year where we looked at NCCN and approved regimens through the National Network of Cancer Centers and we found it was on average 15 days between approval by NCCN and being incorporated into our EMR. So, physicians on average only had to wait 2 weeks for them to be able to have this new regimen, and also some of this comes with new biomarker information so we’ve done the same. We’re incorporating new biomarkers that will direct you to new treatment in the same fashion with the same sort of turnaround time.
Dr Kathy Zackowski Discusses the Importance of Rehabilitation Research and Trials in MS
April 26th 2024Kathy Zackowski, PhD, National MS Society, expresses the inherent value of quality rehabilitation trials for broadening clinical understandings of multiple sclerosis (MS) and bettering patient outcomes.
Read More
The Importance of Examining and Preventing Atrial Fibrillation
August 29th 2023At this year’s American Society for Preventive Cardiology Congress on CVD Prevention, Emelia J. Benjamin, MD, ScM, delivered the Honorary Fellow Award Lecture, “The Imperative to Focus on the Prevention of Atrial Fibrillation,” as the recipient of this year’s Honorary Fellow of the American Society for Preventive Cardiology award.
Listen
Promoting Equity in Public Health: Policy, Investment, and Community Engagement Solutions
June 28th 2022On this episode of Managed Care Cast, we speak with Georges C. Benjamin, MD, executive director of the American Public Health Association, on the core takeaways of his keynote session at AHIP 2022 on public health policy and other solutions to promote equitable health and well-being.
Listen
Standard Criteria for Loss of Ambulation Needed in DMD
April 19th 2024A recent study suggests the differences between ambulation definitions for patients with Duchenne muscular dystrophy (DMD) can impact the identification of ambulant vs nonambulant individuals, and standard criteria across settings are needed.
Read More